Östen Ljunggren

Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia

Kenneth B. Jonsson, R Zahradnik, Tobias E. Larsson et al. · New England Journal of Medicine · 2003 · 907 citations · Full text

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Jan Bolinder, Östen Ljunggren, Joel Kullberg et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 849 citations

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

Tobias E. Larsson, Ulf Nisbeth, Östen Ljunggren et al. · Kidney International · 2003 · 686 citations

Metabolic Syndrome, Nutrition, Urology +11

Transgenic Mice Expressing Fibroblast Growth Factor 23 under the Control of the α1(I) Collagen Promoter Exhibit Growth Retardation, Osteomalacia, and Disturbed Phosphate Homeostasis

Tobias E. Larsson, Richard Marsell, Ernestina Schipani et al. · Endocrinology · 2004 · 496 citations

Human Growth, Pathology, Osteoporosis +17

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Jan Bolinder, Östen Ljunggren, Lars Johansson et al. · Diabetes Obesity and Metabolism · 2013 · 470 citations · Full text